MX357614B - Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas. - Google Patents

Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.

Info

Publication number
MX357614B
MX357614B MX2014010369A MX2014010369A MX357614B MX 357614 B MX357614 B MX 357614B MX 2014010369 A MX2014010369 A MX 2014010369A MX 2014010369 A MX2014010369 A MX 2014010369A MX 357614 B MX357614 B MX 357614B
Authority
MX
Mexico
Prior art keywords
methods
viloxazine
novel
polymorphs
novel polymorphs
Prior art date
Application number
MX2014010369A
Other languages
English (en)
Inventor
Liang Likan
P Bhatt Padmanabh
Dain David
Taquet Jean-Philippe
Pechenov Aleksandr
Tchesnokov Alexei
Mariaux Reynold
Original Assignee
Supernus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supernus Pharmaceuticals Inc filed Critical Supernus Pharmaceuticals Inc
Publication of MX357614B publication Critical patent/MX357614B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Se proporcionan en la presente métodos de fabricación de viloxazina y sus diversas sales, así como también compuestos relacionados con viloxazina, tales como productos de reacción intermedia novedosos y polimorfos de los mismos. En particular, los métodos proporcionan un API sustancialmente puro de HC1 de viloxazina mientras que evita las impurezas indeseables. Los métodos además se proporcionan para separar, identificar y caracterizar polimorfos novedosos de viloxazina. Se proporcionan además métodos para síntesis e identificación y caracterización de intermedios novedosos de viloxazina, así como también algunos metabolitos importantes y precursores de metabolitos de viloxazina.
MX2014010369A 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas. MX357614B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32315110P 2010-04-12 2010-04-12
PCT/US2011/032013 WO2011130194A2 (en) 2010-04-12 2011-04-12 Methods for producing viloxazine salts and novel polymorphs thereof

Publications (1)

Publication Number Publication Date
MX357614B true MX357614B (es) 2018-07-17

Family

ID=44065289

Family Applications (5)

Application Number Title Priority Date Filing Date
MX2014010369A MX357614B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2012011821A MX2012011821A (es) 2010-04-12 2011-04-12 Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010368A MX355697B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010358A MX357613B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010356A MX347218B (es) 2010-04-12 2011-04-12 Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.

Family Applications After (4)

Application Number Title Priority Date Filing Date
MX2012011821A MX2012011821A (es) 2010-04-12 2011-04-12 Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010368A MX355697B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010358A MX357613B (es) 2010-04-12 2011-04-12 Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
MX2014010356A MX347218B (es) 2010-04-12 2011-04-12 Metodos para producir sales de viloxazina y polimorfos novedosos de las mismas.

Country Status (8)

Country Link
US (6) US9403783B2 (es)
EP (1) EP2558437B1 (es)
JP (5) JP6196551B2 (es)
AU (1) AU2011240773C1 (es)
CA (4) CA2992219A1 (es)
ES (1) ES2552166T3 (es)
MX (5) MX357614B (es)
WO (1) WO2011130194A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX357614B (es) 2010-04-12 2018-07-17 Supernus Pharmaceuticals Inc Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
EP3638241B1 (en) * 2017-06-16 2022-05-25 Beta Pharma, Inc. Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
CN108760719A (zh) * 2018-08-17 2018-11-06 北京理工大学 一种利用拉曼光谱分析cl-20的晶型纯度的方法
MX2023010937A (es) * 2021-03-18 2024-03-25 Supernus Pharmaceuticals Inc Derivados de morfolinas sustituidas y usos de estos.
CN118451064A (zh) 2022-03-18 2024-08-06 苏佩努斯制药公司 制备取代吗啉的衍生物的方法
WO2023248154A1 (en) * 2022-06-22 2023-12-28 Glenmark Life Sciences Limited Process for the preparation of viloxazine hydrochloride
EP4317141A1 (en) 2022-08-04 2024-02-07 Curia Spain S.A.U. Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138405A (en) * 1966-12-28 1969-01-01 Ici Ltd Morpholine derivatives
US3857839A (en) * 1969-06-20 1974-12-31 Ici Ltd For cyclising 1-aryloxy-3 beta-substituted ethylamino-2-propanols
US3712890A (en) 1969-06-20 1973-01-23 Ici Ltd Process for making 2-aryloxymethyl morpholines
ES411826A1 (es) * 1973-02-20 1976-01-01 Liade Sa Lab Procedimiento de obtencion de 1-ariloxi - 2 - propanolami- nas farmacologicamente activos.
JPS5188972A (en) 1975-01-29 1976-08-04 22*77 indeniruokishimechiru **4 chikanmoruhorinjudotainoseiho
JPS5283677A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Derivative of 2-(7-indenyloxymethyl)-4-substituted morpholine
US4711887A (en) * 1982-04-23 1987-12-08 Imperial Chemical Industries Plc Hydrazinopyridazine compounds
JPH06306025A (ja) * 1992-11-30 1994-11-01 Sankyo Co Ltd ジアリールアルカン誘導体
US5760069A (en) * 1995-02-08 1998-06-02 Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 Method of treatment for decreasing mortality resulting from congestive heart failure
JPH11511733A (ja) * 1995-03-10 1999-10-12 ナイコムド サルター，インコーポレイテッド Ｎ−アリールメチル−アジリジン誘導体、前記誘導体から得られる１，４，７，１０−テトラアザシクロドデカン誘導体、および、中間体としてのｎ−アリールメチル−エタノールアミンのスルホン酸エステルの製造方法
AUPO565997A0 (en) * 1997-03-17 1997-04-10 Fujisawa Pharmaceutical Co., Ltd. Propanolamine derivatives
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
DE19919153A1 (de) * 1999-04-27 2000-11-02 Consortium Elektrochem Ind Herstellung von acrylierten flüssigkristallinen Verbindungen
FR2796069B3 (fr) * 1999-07-09 2001-08-24 Sanofi Synthelabo Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes
JP2003523382A (ja) * 2000-02-24 2003-08-05 ファルマシア・アンド・アップジョン・カンパニー 新規な薬物の組合せ
US20030040436A1 (en) * 2000-10-23 2003-02-27 Emerson Ralph W. Use of benzyl ester compositions for controlling non-arthropod pest populations
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7326790B2 (en) * 2003-05-02 2008-02-05 Rigel Pharmaceuticals, Inc. Diphenylisoxazole compounds and hydro isomers thereof
JP4210573B2 (ja) * 2003-10-10 2009-01-21 花王株式会社 置換フェノキシプロパノールアミン類
MXPA06013786A (es) * 2004-05-27 2007-01-25 Pfizer Nuevos derivados de aminopiridina y su uso como farmacos.
US20060118002A1 (en) * 2004-12-03 2006-06-08 Sud-Chemie Inc. Organoclay composition containing quat mixtures
BRPI0615705A2 (pt) * 2005-09-06 2016-08-23 Smithkline Beecham Corp processo para preparar um composto, e, composto
PE20070855A1 (es) * 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
CN100415709C (zh) * 2006-05-15 2008-09-03 西北大学 β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途
WO2008047388A2 (en) 2006-10-20 2008-04-24 Ind-Swift Laboratories Limited Improved process for the preparation of ranolazine
EP2285770B1 (en) * 2008-06-02 2015-05-20 Cipla Limited Process for the synthesis of arformoterol
ES2459322T3 (es) * 2008-09-05 2014-05-09 Supernus Pharmaceuticals, Inc. Método de tratamiento de trastorno de déficit de atención con hiperactividad (TDAH)
US9296940B2 (en) * 2009-12-21 2016-03-29 Baker Hughes Incorporated Dithiazine derivatives
MX357614B (es) * 2010-04-12 2018-07-17 Supernus Pharmaceuticals Inc Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
TWI596088B (zh) * 2011-01-25 2017-08-21 陶氏農業科學公司 ４－胺基－６－（經取代的苯基）吡啶甲酸酯及６－胺基－２－（經取代的苯基）－４－嘧啶羧酸酯之芳烷酯以及其等作為除草劑之用途
RU2659036C2 (ru) * 2012-11-21 2018-06-27 Раквалиа Фарма Инк. Полиморфные формы

Also Published As

Publication number Publication date
CA2795408A1 (en) 2011-10-20
US20150126735A1 (en) 2015-05-07
JP2019194191A (ja) 2019-11-07
CA3126096C (en) 2023-11-21
MX347218B (es) 2017-04-20
CA2795408C (en) 2018-03-13
US9434703B2 (en) 2016-09-06
EP2558437B1 (en) 2015-08-05
US20160304475A1 (en) 2016-10-20
WO2011130194A3 (en) 2012-01-05
US9403783B2 (en) 2016-08-02
ES2552166T3 (es) 2015-11-26
JP6196551B2 (ja) 2017-09-13
JP2017039754A (ja) 2017-02-23
JP2016006062A (ja) 2016-01-14
CA3126096A1 (en) 2011-10-20
US10005743B2 (en) 2018-06-26
US20190300492A1 (en) 2019-10-03
JP2018076325A (ja) 2018-05-17
CA3215310A1 (en) 2011-10-20
MX357613B (es) 2018-07-17
WO2011130194A2 (en) 2011-10-20
CA2992219A1 (en) 2011-10-20
JP6663413B2 (ja) 2020-03-11
JP2013530129A (ja) 2013-07-25
AU2011240773B2 (en) 2015-04-02
US20110251198A1 (en) 2011-10-13
US10160733B2 (en) 2018-12-25
AU2011240773C1 (en) 2015-08-27
MX2012011821A (es) 2012-11-30
MX355697B (es) 2018-04-27
EP2558437A2 (en) 2013-02-20
AU2011240773A1 (en) 2012-11-01
US20220024885A1 (en) 2022-01-27
US20180265482A1 (en) 2018-09-20

Similar Documents

Publication Publication Date Title
MX357614B (es) Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas.
IN2012DN02751A (es)
TW201129555A (en) Process for the manufacture of dabigatrane etexilate
EP2206763A4 (en) PROCESS FOR PREPARING A COMPOSITION USING ALCOHOL FROM INITIAL MATERIAL
JO2816B1 (en) A new process for the installation of agililatine
EP2277878A4 (en) METHOD FOR PRODUCING ETHYL HYLTHYMIDINE COMPOUND WITH 5-METHYLURIDINE AS A STARTING MATERIAL
GEP20125512B (en) Process for synthesis of agomelatin
NZ605234A (en) Process for the synthesis of substituted morphinans
EG27128A (en) Process for the production of light olefins from synthesis gas
WO2010028122A8 (en) Process for making bivalirudin
MX350003B (es) Procedimiento para la fabricación de derivados de dibenzoilmetano.
MX2010004546A (es) Nuevos intermedios de pregabalina y procedimiento para prepararlos y para preparar pregabalina.
MX2012006524A (es) Proceso para la sintesis de compuestos intermedios de utilidad para preparar compuestos sustituidos de indazol y azaindol.
MX2012002818A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
GEP20115344B (en) New process for synthesis of agomelatine
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
UA102816C2 (ru) Способ синтеза кристаллической формы v агомелатина
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
MX2013004193A (es) Procedimiento para la preparacion de derivados de acido 3-(6-amino-piridin-3-il)-2-acrilico.
IN2012DN02000A (es)
WO2013072766A3 (en) Process for cabazitaxel and intermediates thereof
WO2013072936A3 (en) A novel process for the preparation of (r)-n-benzyl-2 acetamido-3-methoxypropionamide
WO2012050623A3 (en) Novel phenoxyisobutyric acid compounds and methods for synthesis
WO2014060575A3 (en) Process for the enantioselective synthesis of a tetrahydrobenzazepine compound
WO2011151442A3 (en) Process for producing aliskiren